Background: 2-Cl-C.OXT-A (COA-Cl) is a novel synthesized adenosine analog that activates 28 S1P1 receptor (S1P1R) and combines with adenosine A1 receptor (A1R) in G proteins and was 29
Introduction 52
Positive inotropic agents are considered to enhance the hemodynamic profile in terms of 53 elevating the cardiac output, decreasing the cardiac filling pressure, and improving the organ 54 perfusion in patients with heart disease. In clinical trials in which inotropic agents were 55 administered to promote the contraction of the dysfunctional heart, safety was a concern from 56 the viewpoint of the long-term prognosis [1] . However, in the clinical setting, inotropic agents 57 remain a major treatment for patients in the decompensated phase of severe heart failure. 58
Positive inotropic drugs are useful for increasing the cardiac output in order to resolve various 59 problems associated with heart failure, especially for patients with a low systolic blood pressure 60 or low cardiac output [2] . 61 COA-Cl is a novel nucleic acid analogue that has been found to promote angiogenesis. angiogenesis and synaptogenesis in vivo in a model of ischemia [6] . Focusing on the chemical 66 structure of COA-Cl, we hypothesized that the structure would be similar to that of xanthine 67 derivatives, which act as nonspecific inhibitors of PDE [7] . We predicted that COA-Cl would 68 act as an inhibitor of PDE and exert a positive inotropic effect on the heart. In order to evaluate 69 the effect in vitro, we used cardiac organoids composed of human-derived cells. Cardiac 70 myocytes and fibroblasts determine the structural, mechanical, and electrical characteristics of 71 the myocardium [8] . Studies of cardiac myocytes and fibroblasts in two-dimensional (2D) cell 72 cultures have provided valuable information on their biology and regulation. However, cells 73 grown on a flat hard surface are exposed to a different environment from the tissue [9] . 74
Human induced pluripotent stem cells (hiPSCs) are expected to be a useful source of 75 cells for drug discovery and autogenous transplantation [10] [11] [12] . We have been 76 7 First, we measured the half maximal inhibitory concentration (IC50) of COA-Cl with a Lance 132 Ultra cAMP kit (Perkin-Elmer, Beverly, MA, USA). In brief, pure hiPSC-CM spheroids were 133 dissociated by incubation with AccuMax TM (PAA Laboratories, Cölbe, Germany) for 60 min 134 at 37 °C and pipetting every 15 min. The cell pellet was resuspended in HBSS (Hank's 135
Balanced Salt Solution) containing 5 mM HEPES and 0.5 mM IBMX (pH 7.4). This cell 136 suspension was then treated according to the manufacturer's instructions (LANCE Ultra cAMP 137
Kit, Perkin-Elmer). The cell suspension (5 μl containing approximately 1,000 cells) was added 138 to 5 μl of agonist solution and allowed to incubate for 30 min at room temperature in an 139
OptiPlate 384-well plate (Perkin-Elmer). The detection mix containing Eu-cAMP tracer and 140
ULight-anti-cAMP was added and allowed to incubate for 1 h. The assay was read on a 141
Flexstation 3 system (LANCE settings: 340 nm Ex/665 nm Em; Molecular Devices, Sunnyvale, 142 CA, USA). The cAMP standards included with the kit and cell suspensions stimulated with 143 HBSS (containing IBMX) only served as the standard curve and internal controls, respectively. 144
After determining the IC50 of COA-Cl, we compared the cAMP levels after the application of 145 several compounds (phosphate-buffered solution [PBS] as a control and Propranolol, 146
Isoproterenol, SEW2871, Forskolin, or COA-Cl) using a Lance Ultra cAMP kit. The plate was 147 then read using an Envision multi-label plate reader (Perkin-Elmer). 148
149
The PDE activity assay of pure hiPSC-CM spheroids 150
Pure hiPSC-CM spheroids were pre-treated with COA-Cl or control (PBS) for 30 min. These 151 spheroids were dissociated by incubation with AccuMax TM for 60 min at 37 °C and pipetting 152 every 15 min. After incubation, these cells in 300 µl lysis buffer were briefly centrifuged at 153 20,000×g for 10 min at 4 °C. The lysed cells were then incubated with the substrate cAMP at 154 37 °C for 10 min, and using a PDE activity assay kit (Abcam, Inc., Cambridge, MA), the PDE 155 activity was measured by reading at OD 620 nm on an Envision multi-label plate reader.
157
The histological analysis and immunohistochemistry of cardiac organoids. 158
Samples were collected with collagen gels, fixed with 4% paraformaldehyde PBS (Wako, 159
Osaka, Japan), and embedded in paraffin. Sections (4-6 µm) were mounted on microscope 160 slides after dewaxing and rehydration. Antigen retrieval was performed in Dako pH 9 EDTA 161 buffer (Dako, Kyoto, Japan) with a microwave. Sections were incubated with primary 162 Oberkochen, Germany) using a ×40 oil immersion. 182
183

Statistical analyses 184
All data are expressed as the mean ± standard deviation, and all statistical comparisons were 185 determined by a one-way analysis of variance followed by Tukey's test or a two-tailed Student's 186 t-test. All statistical analyses were performed using the Excel and JMP software programs (SAS 187
Institute, Cary, NC). 188
189
Results
190
A histological analysis and immunohistochemistry of cardiac organoids 191
Phase contrast microscopy revealed the spheroid morphology of cardiac organoids ( Fig. 2A) . 192
Spindle and polygonal cells were shown to be mixed in cardiac organoids (Fig. 2B) . positive endothelial cells were scattered in cardiac organoids (Fig. 2C ). Cardiac myocytes, 194
shown as troponin T-positive cells, were located diffusely inside cardiac organoids (Fig. 2D) . 195
HDFBs were also distributed inside cardiac organoids (Fig. 2E ). In addition, cardiac organoids 196 were fixed with 4% paraformaldehyde were immunostained with troponin T to indicate the 197 details of cardiac myocytes. The sample was observed with a scanning microscope (Fig. 2F) . 
Effects of COA-Cl on the beating and contraction of cardiac organoids 202
Research using disease models and drug screening systems with hiPSC-CMs is advancing 203 rapidly. The tissue-engineered cardiac system with stem cells has become quite useful since 204 the development of a more sensitive drug test model and an improved cell delivery strategy. 205
The cardiac organoids in our study were composed of hiPSC-CMs, hiPSC-ECs, and HDFBs. 206 First, they were immunostained with CD31, and tube formation was observed. Cardiac 207 myocytes were also immunostained with Troponin T in order to observe the cardiac myocytes 208 of the organoids in detail. HDFBs were also immunostained with CD90. Cardiac organoids 209 fixed with 4% paraformaldehyde phosphate-buffered solution were also stained with troponin 210 T antibody and observed with a confocal microscope. 211
Based on our findings, the cardiac organoids were determined to be a cardiac model 212 with a vascular network. The effect of COA-Cl on the cardiac organoids was then investigated 213 by observing this model before and after the addition of the drug. The movements of the cardiac 214 organoids created and cultured for 10 days were observed. The beatings were recorded for 30 215 seconds. COA-Cl (1 mM) was then added, and the cardiac organoids were incubated for 30 216 min and recorded again. The fractional area change was determined from these recordings (Fig.  217   3A) . The changes in the fractional area predominantly increased after the administration of 218 COA-Cl. There was also a remarkable increase in the beating rate (10.7±0.7 beats/min, N=3), 219
and COA-Cl (25.3±0.7 beats/min, N = 3) (Fig. 3B) . 220
221
Effects of COA-Cl on the beating of pure hiPSC-CM spheroids 222
We tested the direct effects of COA-Cl on the beating rate of pure hiPSC-CM spheroids, which 223 may be a valuable phenotypic parameter for drug discovery and development. A cardiac 224 beating assay was performed to assess several positive and negative inotropic effects. 225
Positive chronotropic agents were Isoproterenol and Forskolin, which increase the 226 amount of cAMP in cardiac myocytes and induce a positive inotropic effect. The negative 227 inotropic agent was Propranolol, a nonselective β-blocker that inhibits the binding of 228 norepinephrine (released from sympathetic nerve terminals) to the alpha-1 receptors. In 229 addition, SEW2871 (S1P1 specific agonist) was used for the comparison with COA-Cl. The 230 results from a representative experiment are shown in Fig. 4A . The beating rates of pure hiPSC-231 CM spheroids increased 30 min after the application of Isoproterenol and Forskolin. In contrast, 232 these rates decreased after the application of Propranolol. SEW28171, an S1P1-specific agonist, 233 did not increase the beating rate. The mean beating rates (±standard error of the mean) of the 234 drug-free controls were as follows: vehicle (61.5±1.0 beats/min, N=4), Isoproterenol (91.0±0.6 235 beats/min, N=4), Propranolol (57.5±2.2 beats/min, N=4), Forskolin (99.5±0.5 beats/min, N=4), 236 SEW2871 (62.5±1.0 beats/min, N=4), and COA-Cl (77.5±0.5 beats/min, N=4) (Fig. 4A) . 237
These results suggest that COA-Cl has the potential to increase the beating rate of pure hiPSC-238 CM spheroids, which is well known to indicate positive inotropic effects. However, the 239 mechanism through which the beating is increased differs from that underlying the increase in 240 beating that occurs with S1P1 activation. 241
We also observed the concentration-dependent changes in the beating rate. COA-Cl (1 mM), the beating rate was 1.5-fold faster than before the administration. These 251 results show that COA-Cl is strongly related to some types of receptor and ion channel 252 phosphorylation because the effects occurred immediately after its administration. 253
Overall, these data demonstrate that pure hiPSC-CM spheroids mimic the cellular and 254 molecular composition of human heart tissue. Thus, the beating rate of pure hiPSC-CM 255 spheroids may be a valuable phenotypic parameter for use in drug discovery and development. 256 COA-Cl was found to have positive inotropic effects with pure hiPSC-CM spheroids. 257
258
Effects of COA-Cl on the cAMP lefels of pure hiPSC-CM spheroids 259
The baseline cAMP accumulation of hiPSC-CMs was evaluated with increasing concentrations 260 of Forskolin (100 mM to 1 nM, half-log increments) and time-resolved fluorescence resonance 261 energy transfer (TR-FRET). cAMP standards were used to construct a TR-FRET-concentration 262 curve and calculate the amount of cAMP (Fig. 6A) . The baseline cAMP concentrations, as 263 determined by the Forskolin method, showed a dynamic range of 1 nM to 100 µM (Fig. 6B) . 264 increments) caused a concentration-dependent decrease in TR-FRET and thus an increase in 266 cAMP. In contrast, SEW2871 (1 pM to 1 µM; half-log increments) caused no concentration-267 dependent change in TR-FRET. These data indicate that COA-Cl increases the cAMP 268 concentration in pure hiPSC-CM spheroids via a different mechanism from SEW2871, and we 269 determined that the IC50 of COA-Cl was 1 mM. We then compared the results with vehicle 270 (PBS), Isoproterenol IC50, Forskolin, Propranolol, and SEW2871. Forskolin, ISO, and COA-271
Cl showed additive effects in the total cAMP produced. In contrast, Propranolol and SEW2871 272 had no remarkable effect on the total cAMP production. These data were very similar to those 273 obtained in the beating analysis. COA-Cl has also been reported to bind to the A1R; however, 274 its action was not clear. We confirmed that COA-Cl increases the cAMP levels of hiPSC-CMs 275 through the A1R. These cells were incubated with Suramin (100 μM) for 1 h followed by 276 incubation with several compounds and measurement of the cAMP levels. These data indicated 277 that the inhibition of the A1R by Suramin was not involved in the increase in the cAMP 278 concentrations of hiPSC-CMs (Fig. 6E, 6F) . 279
In conclusion, the mechanism through which COA-Cl increases the cAMP levels does 280 not involve S1P1R or A1R, which are known to be COA-Cl-binding receptors. COA-Cl 281 increased the cAMP levels of hiPSC-CMs similarly to Isoproterenol and Forskolin. 282
283
Effects of COA-Cl on PDE in pure hiPSC-CM spheroids 284
Previous studies have shown that xanthine derivatives act as nonspecific inhibitors of PDE. 285
The action of xanthine derivatives is mainly due to the increase in the intracellular cAMP 286 concentration as a second messenger by the inhibition of PDE. Theophylline is a powerful 287 bronchodilator that is used to treat respiratory diseases, such as COPD (chronic obstructive 288 14 pulmonary disease) [16] . It is also known to have a positive inotropic effect on the heart [17] . 289 COA-Cl is a nucleic acid analog that is structurally similar to a xanthine derivative (Fig. 7A) . 290
We hypothesized that COA-Cl was involved in the elevation of cAMP in cardiac 291 myocytes through its action as a PDE inhibitor. To explain the cause of cAMP elevation, we 292 investigated the activity of the PDE using hydrolyzing cAMP time-course and found that the 293 administration of COA-Cl reduced the PDE activation in comparison to control in hiPSC-CMs 294 (Fig. 8) . This result suggests that COA-Cl may promote the cAMP elevation of hiPSC-CMs 295 and is involved in the increasing pulsation of pure hiPSC-CM spheroids. 296
297
Discussion 298
In this study, we showed that COA-Cl suppresses PDE and increases the contraction of cardiac 299 organoids, independent of S1P1R and A1R. COA-Cl can produce signaling molecules and tube 300 formation in cultured human vascular endothelial cells through S1P1R-mediated extracellular 301 stimulation [3]. COA-Cl has been shown to exert a neuroprotective effect against intracerebral 302 hemorrhaging [6]. It has also been reported that COA-Cl may reduce oxidative stress, which 303 may be one of the mechanisms underlying its neuroprotective effect [5] . In addition, in the 304 perfused heart, pretreatment with S1P has been shown to significantly restore the heart function 305 after ischemia. Interestingly, the protective effect of ischemic preconditioning on 306 ischemia/reperfusion injury was promoted in the hearts of rats treated with S1P1R and S1P3R 307
antagonists [18][19]. 308
COA-Cl is a small molecule that is slightly similar to adenosine. It was hypothesized 309 that it may bind to the G protein-coupled receptor (GPCR) rather than receptor tyrosine kinase 310 (RTK). COA-Cl was shown, through an exhaustive investigation, to act as an agonist of S1P1R 311 and to bind to adenosine A1R [3] . However, the effects of A1R are still unknown. COA-Cl is 312 considered to be a partial stimulator of S1P1R. S1P1R couples with the Gi family of guanine 313 nucleotide-binding regulatory proteins (G-proteins) to activate multiple intracellular signaling 314 pathways, including the extracellular signal-regulated kinase 1, 2 (ERK 1/2) pathways [3]. It 315 has been shown that S1P1R activates sprouting angiogenesis and maintains blood vessel 316 stability in endothelial cells, while S1P1R antagonism inhibits tumor vascularization [20] [21] . 317 However, the mechanisms underlying these potent effects of COA-Cl have remained unclear. 318
To facilitate drug discovery, we created cardiac organoids and then predicted the effects 319 of COA-Cl on the heart and analyzed these functions using the cardiac organoids. We 320 discovered that COA-Cl enhances the pulsatile and contractile power and that increases the 321 cAMP level via the partial inhibition of PDE. Clinically, PDE inhibitors are positive inotropic 322 drugs that are useful for treating heart failure. These contractile actions ultimately increase the 323 Ca 2+ release of the sarcoplasmic reticulum (PDE) by activating cAMP-PKA. It has also been 324 reported that the cAMP and cGMP-PDE activities after ischemic preconditioning are higher 325 than in non-preconditioned hearts and hearts with elevated levels of cGMP [22] . organoids, it is difficult to make them without certain materials, such as hydrogel [28] . We 343 made cardiac organoids without any materials. We also successfully fabricated a 3D tubular 344 structure made of spheroids with a scaffold-free bio 3D printer to make small-caliber vascular 345 The application of hiPSC-derived cells to tissue engineering has also been a focus of 352 research. Since the presence of a cell matrix strongly influences the beating of the heart muscle, 353 we decided to create an organoid that mimics the heart with fibroblasts and endothelial cells. 354
These organoids therefore reflect the heart in vitro. However, there are few reports on the 355 partial shortening of the 3D cardiac structure without scaffolds. Partial shortening was 356 observed in a study of Mukae et al., wherein the authors monitored 2 points (using a software 357 program) with a 2D cardiac patch, and approximately 2%-3% area changes was observed [35] . 358
Richards et al. compared the adult-stage heart with the developing-stage heart by making 359 cardiac organoids and measuring their fractional change [36] . We investigated the contractile 360 action in a human cardiac organoid model with and without COA-Cl by observing the 361 fractional area change and the beating rate of cardiac organoids. Using these techniques, we 362 prepared mixed spheroids derived from hiPSCs and evaluated the drug effect on the cardiac 363 organism based on the beating rate and area change. 364
In our study, we examined the effect of the novel nucleic acid analogue COA-Cl on the 365
heart. In order to analyze cardiotonic drugs in vitro, cardiac organoids composed of hiPSC-366 derived cells were constructed. COA-Cl resulted in pulsatility and contraction changes in the 367 human heart model. Similarly to other cardiotonic drugs, COA-Cl increased the intracellular 368 cAMP level. It was confirmed that its PDE inhibiting effect was one factor that increased the 369 cAMP level. 370
COA-Cl is a xeno-free compound and may therefore be safely applied in regenerative 371 medicine. The growth of cells in vitro usually involves a basal medium supplemented with 372 FBS, which is associated with a risk of disease transmission. Furthermore, growth factors such 373 as VEGF and FGF are fragile and may be subject to considerable lot-to-lot variability [37] . 374
Thus, in tissue engineering with transplantation in mind, the culture of tissues under serum-375 free condition with substances that are not antigenic is required. As COA-Cl is a stable nucleic 376 analogue, it can be applied to tissue engineering for regenerative medicine. 377
378
Conclusion 379
COA-Cl was shown to act as a partial PDE inhibitor of cardiac organoids. Cardiac organoids 380 are useful for drug discovery, facilitating assay performance. The results of the present study 381 suggest their possible application in cardiac transplantation for regenerative medicine. COA-382
Cl can be used as a cardiac inotropic agent, as a partial PDE inhibitor, and to promote 383 angiogenesis in patients with ischemic heart disease and heart failure. 
